Viridian TherapeuticsVRDN
About: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Employees: 143
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
88% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 42
75% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 24
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
8% more funds holding
Funds holding: 165 [Q3] → 178 (+13) [Q4]
1.06% more ownership
Funds ownership: 113.88% [Q3] → 114.94% (+1.06%) [Q4]
12% less capital invested
Capital invested by funds: $1.98B [Q3] → $1.75B (-$233M) [Q4]
52% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $20.4M
Research analyst outlook
We haven’t received any recent analyst ratings for VRDN.
Financial journalist opinion









